Survey: Illumina, SOLiD, and 454 Gain Ground in Research Labs; Most Users Mull Additional Purchases

Although most of the 50 labs polled in the survey own only a single type of next-gen sequencing platform, more than two-thirds of survey respondents said they plan to purchase another high-throughput sequencer in the next 12 to 18 months.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.